इन्फ्लुएंजा क्या है?

Dengue, or dengue fever, is a viral illness caused by infection with the dengue virus (DENV).

DENV is a single‑stranded RNA virus that, like yellow fever virus और Japanese encephalitis virus, belongs to the genus Flavivirus. There are four serotypes of DENV. Immunity against one serotype does not provide protection against the other serotypes, meaning a person can experience dengue more than once in their lifetime. Severe disease is more likely with subsequent infections.

किन लक्षणों पर नज़र रखने की आवश्यकता है?

Dengue has an incubation period of 3 to 14 days. Most people who are infected experience no symptoms or have mild symptoms which resolve in 1 to 2 weeks. Common symptoms include:

  • high fever (40°C)
  • severe headache
  • muscle and joint pains
  • खरोंच
  • pain behind the eyes
  • abdominal pain, nausea and vomiting
  • swollen glands.

In rare cases, infection can progress to severe disease (dengue haemorrhagic fever, dengue shock syndrome) and display symptoms of severe abdominal pain, haematemesis (vomit with blood in it), tachypnoea (rapid breathing), bleeding from the gums or nose, fatigue, lethargy, pale and cold skin, or other unexplained bleeding. Severe dengue is a medical emergency.

यह कैसे संचारित होता है?

DENV is primarily transmitted to humans via mosquitoes. Humans who are symptomatic can transmit the virus 2 days prior to symptom onset until 2 days after the fever has resolved. Asymptomatic cases (without symptoms) are also infectious. In rare cases, DENV can be transmitted through mucous membranes, blood transfusions, needle stick injuries and organ transplants. Maternal transmission during pregnancy (from mother to infant) has been reported and is linked to pre‑term birth, low birthweight and post‑partum haemorrhage (severe bleeding).

एपिडेमियोलॉजी (महामारी विज्ञान)

Dengue is now endemic in more than 100 countries across tropical and sub‑tropical areas in the Pacific, Asia, Africa and the Americas. There were 14.6 million cases of dengue reported to the World Health Organization (WHO) in 2024.

DENV is not routinely found in Australia although imported cases (where a person is infected overseas) do occur. Mosquitoes capable of carrying dengue can be found in central and northern Queensland, the Northern Territory, northern Western Australia, and the Torres Strait. Local outbreaks of dengue, although rare, have historically occurred in northern Queensland and the Torres Strait.

रोकथामं

वास्तविक बाधाएं

The mosquitoes capable of carrying dengue are active during the day. Care should be taken to avoid exposure by:

  • बाहर जाने पर लंबे, ढीले-ढाले कपड़े पहनना
  • पिकारिडिन या डीईईटी युक्त मच्छर निरोधकों का उपयोग करना
  • यदि बहुत सारे मच्छर हों तो बाहरी गतिविधियों को सीमित कर दें
  • using fly sprays, mosquito coils and plug‑in repellent devices
  • sleeping under mosquito nets treated with insecticides if sleeping indoors where windows, doors and vents are not covered by insect‑proof mesh (flywire screens), or if sleeping outdoors in an untreated tent or in the open.

Vaccination

Dengvaxia is a live‑attenuated recombinant tetravalent vaccine used for the prevention of

dengue infections only. It is given as a 3‑dose course, with 6 months between each dose, and is suitable only where the all following conditions are met:

  • Aged 9–45 years
    और
  • Previously infected with DENV
    और
  • Intending to reside in highly dengue
    endemic regions for extended periods
    और
  • The potential benefits of vaccination outweigh the risks.

It is only available through the Special Access Scheme (SAS), on a case‑by‑case basis, through specific application to the Therapeutic Goods Administration (TGA).

मतभेद और सावधानियां

Dengvaxia is not safe for people who have never been infected with DENV before. Given approximately 40 to 80% of dengue infections are asymptomatic and there is no blood test sensitive enough to adequately confirm previous immunity, identifying who can safely be vaccinated is challenging.

Dengvaxia has been linked to vaccine-associated enhanced disease (VAED), a rare phenomenon where a person who has been vaccinated experiences a (usually) more severe clinical presentation of an infection than would normally be seen in an unvaccinated person.

It is a live-attenuated vaccine and therefore must not be given during गर्भावस्था or to immunosuppressed individuals.

लेखक: Katie Butler (MVEC Education Nurse)

द्वारा समीक्षित: Rachael McGuire (MVEC Education Nurse Coordinator) and Linny Phuong (Paediatric Infectious Diseases Physician, MCRI)

तारीख: March 2026

नई जानकारी और टीके उपलब्ध होते ही इस अनुभाग की सामग्रियों को अद्यतन किया जाता है। मेलबर्न वैक्सीन एजुकेशन सेंटर (MVEC) कर्मचारी सटीकता के लिए नियमित रूप से सामग्रियों की समीक्षा करते हैं।

आपको इस साइट में प्रदान की गई जानकारी को अपने व्यक्तिगत स्वास्थ्य या अपने परिवार के व्यक्तिगत स्वास्थ्य के लिए विशिष्ट, पेशेवर चिकित्सीय सलाह नहीं मानना चाहिए। चिकित्सीय संबंधी चिंताओं के लिए जिसमें टीकाकरण, दवाओं और अन्य उपचारों के बारे में निर्णय लेना शामिल है, आपको हमेशा स्वास्थ्य देखभाल पेशेवर से परामर्श लेना चाहिए।

MVEC acknowledges the traditional owners of the lands on which we live, work and educate. We pay our respects to their Elders, past, present and emerging.
We are committed to honouring Australian Aboriginal and Torres Strait Islander peoples’ unique cultural and spiritual relationships to the land, waters and seas.

एमवीईसी के बारे में

मेलबोर्न वैक्सीन एजुकेशन सेंटर (एमवीईसी) एक शैक्षिक वेबसाइट है, जिसे स्वास्थ्य सेवा पेशेवरों और जनता के सदस्यों दोनों के लिए अद्यतित टीकाकरण जानकारी प्रदान करने के उद्देश्य से विकसित किया गया है। हम मर्डोक चिल्ड्रन्स रिसर्च इंस्टीट्यूट (MCRI), एक शोध संगठन पर आधारित हैं, और SAEFVIC (समुदाय में टीकाकरण के बाद प्रतिकूल घटनाओं की निगरानी), विक्टोरियन वैक्सीन सुरक्षा सेवा से संबद्ध हैं।

इसे साझा करें